Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced ...

(Reuters) -Health and Human Services Secretary Robert F. Kennedy Jr. said on Thursday that the U.S. drugs regulator would ...

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a ...

DataM Intelligence | competitive Intelligence Gene therapies, exon-skipping drugs and next-gen steroids are reshaping Duchenne muscular dys ...

Visit a quote page and your recently viewed tickers will be displayed here.

Get the latest news and real-time alerts from Dyne Therapeutics, Inc. (DYN) stock at Seeking Alpha. Skip to content Home page Seeking ... APGE Apogee Therapeutics, Inc. 0 0.00% 0.00% Compare ...

Another element that sets digital therapeutics apart was outlined by Ben Lewis, CEO of Limbix, a developer of prescription digital therapeutics, who told pharmaphorum that the company has a ...

Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation ...

UK biotech Bicycle Therapeutics has raised £40 million ($52m) in a new funding round to help it progress its pipeline, including its lead compound, a first-in-class cancer treatment. The company ...